Research

Mixed

Roux-en-Y gastric bypass (RYGB) and Health Behavior Intervention (HBI) are cost-effective strategies for managing class III obesity, whereas current-price pharmacotherapies (semaglutide and tirzepatide) are not cost-effective compared to no treatment or HBI.

For individuals with class III obesity, Roux-en-Y gastric bypass offers the best long-term health outcomes and cost-effectiveness. Health Behavior Intervention (13 counseling sessions) is also cost-effective. Current GLP-1/GIP medications are not cost-effective at current prices, though lower prices could change this.

GoodQualifiesHIGH confidence
RYGB and HBI are cost-effective for managing class III obesity. While RYGB provided the greatest health gains, access remains limited. Neither pharmacotherapy was cost-effective at current prices.
Nisha Gupta et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

High-quality economic modeling based on published clinical trial data (STEP, SURMOUNT) and real-world adherence rates.

Source

A cost‐effectiveness analysis of behavioural, pharmacological, and surgical obesity treatments in Canada

Nisha Gupta et al. · Diabetes Obesity and Metabolism · 2025

DOI 10.1111/dom.16627

unknownCited 3×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →